<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0512222979
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CYMBALTA 60MG HARD GASTRO-RESISTANT CAP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DULOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        112.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Lilly Del Caribe, Inc." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Lilly Del Caribe, Inc.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ELI LILLY NEDERLAND B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cymbalta contains the active substance duloxetine. Cymbalta increases the levels of serotonin and noradrenaline in the nervous system.</p><p>Cymbalta is used in adults to treat:</p><p>&middot;&nbsp; Major Depressive Disorder (MDD).</p><p>&middot;&nbsp; Diabetic Peripheral Neuropathic Pain (DPNP) (often described as burning, stabbing, stinging, shooting or aching or like an electric shock. There may be loss of feeling in the affected area, or sensations such as touch, heat, cold or pressure may cause pain)</p><p>Cymbalta starts to work in most people with depression or anxiety within two weeks of starting treatment, but it may take 2-4 weeks before you feel better. Tell your doctor if you do not start to feel better after this time. Your doctor may continue to give you Cymbalta when you are feeling better to prevent your depression or anxiety from returning.</p><p>In people with diabetic neuropathic pain it can take some weeks before you feel better. Talk to your doctor if you do not feel better after 2 months.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DO NOT take Cymbalta if you:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking or have taken within the last 14 days, another medicine known as a monoamine oxidase inhibitor (MAOI) (see &lsquo;Other medicines and Cymbalta&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or enoxacin which are used to treat some infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines containing duloxetine (see &lsquo;Other medicines and Cymbalta&rsquo;)</p><p>Talk to your doctor if you have high blood pressure or heart disease. Your doctor will tell you if you should be taking Cymbalta.</p><p><strong>Warnings and precautions:</strong></p><p>The following are reasons why Cymbalta may not be suitable for you. Talk to your doctor before you take Cymbalta if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines to treat depression (see &lsquo;Other medicines and Cymbalta&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking St. John&rsquo;s Wort, a herbal treatment (<em>Hypericum perforatum</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had seizures (fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had mania</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from bipolar disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have eye problems, such as certain kinds of glaucoma (increased pressure in the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of bleeding disorders (tendency to develop bruises), especially if you are pregnant (see &lsquo;Pregnancy and breast-feeding&lsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are currently being treated with another medicine which may cause liver damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines containing duloxetine (see &lsquo;Other medicines and Cymbalta&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. Cymbalta may harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take Cymbalta during pregnancy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Cymbalta.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. Cymbalta passes into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby while taking Cymbalta.</p><p><br />Cymbalta may cause a sensation of restlessness or an inability to sit or stand still. You should tell your doctor if this happens to you.</p><p>Medicines like Cymbalta (so called SSRIs/SNRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms have continued after stopping treatment.</p><p><strong><em>Thoughts of suicide and worsening of your depression or anxiety disorder</em></strong></p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously had thoughts about killing or harming yourself</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant</p><p><strong>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</strong></p><p>You may find it helpful to tell a relative or close friend that you are depressed or have<em> </em>an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p><strong><em>Children and adolescents under 18 years of age</em></strong></p><p>Cymbalta should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Cymbalta for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Cymbalta for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Cymbalta. Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of Cymbalta in this age group have not yet been demonstrated.</p><p><strong>Other medicines and Cymbalta</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.</p><p>The main ingredient of Cymbalta, duloxetine, is used in other medicines for other conditions:</p><p>&middot;&nbsp;&nbsp; diabetic neuropathic pain, depression, anxiety and urinary incontinence</p><p>Using more than one of these medicines at the same time should be avoided. Check with your doctor if you are already taking other medicines containing duloxetine.</p><p>Your doctor should decide whether you can take Cymbalta with other medicines. <strong>Do not start or stop taking any medicines, including those bought without a prescription and herbal remedies, before checking with your doctor.</strong></p><p>You should also tell your doctor if you are taking any of the following:</p><p><strong><em>Monoamine oxidase inhibitors (MAOIs):</em></strong><strong> </strong>You should not take Cymbalta if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI). Examples of MAOIs include moclobemide (an antidepressant) and linezolid (an</p><p>antibiotic). Taking a MAOI together with many prescription medicines, including Cymbalta, can cause serious or even life-threatening side effects. You must wait at least 14 days after you have stopped taking an MAOI before you can take Cymbalta. Also, you need to wait at least 5 days after you stop taking Cymbalta before you take a MAOI.</p><p><strong><em>Medicines that cause sleepiness:</em></strong> These include medicines prescribed by your doctor including benzodiazepines, strong painkillers, antipsychotics,<strong> </strong>phenobarbital and antihistamines.</p><p><strong><em>Medicines that increase the level of serotonin:</em></strong><em> </em>Triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), SNRIs (such as venlafaxine), tricyclic antidepressants (such as clomipramine, amitriptyline), pethidine, St John&rsquo;s Wort and MAOIs (such as moclobemide and linezolid). These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Cymbalta, you should see your doctor.</p><p><strong><em>Oral anticoagulants or antiplatelet agents:</em></strong> Medicines which thin the blood or prevent the blood from clotting. These medicines might increase the risk of bleeding.</p><p><strong>Cymbalta</strong> <strong>with food, drink and alcohol</strong></p><p>Cymbalta may be taken with or without food. Care should be taken if you drink alcohol while you are being treated with Cymbalta.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you become pregnant, or you are trying to become pregnant, while you are taking Cymbalta. You should use Cymbalta only after discussing the potential benefits and any potential risks to your unborn child with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure your midwife and/or doctor knows you are on Cymbalta. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take Cymbalta near the end of your pregnancy, your baby might have some symptoms when it is born. These usually begin at birth or within a few days of your baby being born. These symptoms may include floppy muscles, trembling, jitteriness, not feeding properly, trouble with breathing and fits. If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s health, contact your doctor or midwife who will be able to advise you.</p><p>If you take Cymbalta near the end of your pregnancy there is an increased risk of excessive vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking duloxetine so they can advise you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Available data from the use of Cymbalta during the first three months of pregnancy do not show an increased risk of overall birth defects in general in the child. If Cymbalta is taken during the second half of pregnancy, there may be an increased risk that the infant will be born early (6&nbsp;additional premature infants for every 100&nbsp;women who take Cymbalta in the second half of pregnancy), mostly between weeks 35 and 36 of pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are breast-feeding. The use of Cymbalta while breastfeeding is not recommended. You should ask your doctor or pharmacist for advice.</p><p><strong>Driving and using machines</strong></p><p>Cymbalta may make you feel sleepy or dizzy. Do not drive or use any tools or machines until you know how Cymbalta affects you.</p><p><strong>Cymbalta contains sucrose</strong></p><p>Cymbalta contains <strong>sucrose.</strong> If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>Cymbalta contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Cymbalta is for oral use. You should swallow your capsule whole with a drink of water.</p><p><em>For depression and diabetic neuropathic pain: </em></p><p>The usual dose of Cymbalta is 60&nbsp;mg once a day, but your doctor will prescribe the dose that is right for you.</p><p>To help you remember to take Cymbalta, you may find it easier to take it at the same times every day.</p><p>Talk with your doctor about how long you should keep taking Cymbalta. Do not stop taking Cymbalta, or change your dose without talking to your doctor. Treating your disorder properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and difficult to treat.</p><p><strong>If you take more Cymbalta</strong> <strong>than you should</strong></p><p>Call your doctor or pharmacist immediately if you take more than the amount of Cymbalta prescribed by your doctor. Symptoms of overdose include sleepiness, coma, serotonin syndrome (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits, vomiting and fast heart rate.</p><p><strong>If you forget to take Cymbalta</strong></p><p>If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten dose. Do not take more than the daily amount of Cymbalta that has been prescribed for you in one day.</p><p><strong>If you stop taking Cymbalta</strong></p><p>DO NOT stop taking your capsules without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need Cymbalta he or she will ask you to reduce your dose over at least 2 weeks before stopping treatment altogether.</p><p>Some patients who stop taking Cymbalta suddenly have had symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.</p><p>These symptoms are usually not serious and disappear within a few days, but if you have symptoms that are troublesome you should ask your doctor for advice.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate and often disappear after a few weeks.</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp; &nbsp;headache, feeling sleepy</p><p>&middot;&nbsp;&nbsp; &nbsp;feeling sick (nausea), dry mouth</p><p><strong>Common side effects </strong><strong>(may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping, feeling agitated, less sex drive, anxiety, difficulty or failure to experience orgasm, unusual dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, feeling sluggish, tremor, numbness, including numbness, pricking or tingling of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tinnitus (hearing sound in the ear when there is no external sound)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling the heart pumping in the chest,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure, flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased yawning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, diarrhoea, stomach pain, being sick (vomiting), heartburn or indigestion, breaking wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating, (itchy) rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, muscle spasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination, frequent urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems getting an erection, changes in ejaculation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls (mostly in elderly people), fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>Children and adolescents under 18 years of age with depression treated with this medicine had some weight loss when they first start taking this medicine. Weight increased to match other children and adolescents of their age and sex after 6 months of treatment.</p><p><strong>Uncommon side effects </strong><strong>(may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat inflammation that causes a hoarse voice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal thoughts, difficulty sleeping, grinding or clenching the teeth, feeling disorientated, lack of motivation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden involuntary jerks or twitches of the muscles, sensation of restlessness or an inability to sit or stand still, feeling nervous, difficulty concentrating, changes in sense of taste, difficulty controlling movement e.g. lack of coordination or involuntary movements of the muscles, restless legs syndrome, poor sleep quality</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large pupils (the dark centre of the eye), problems with eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of dizziness or &ldquo;spinning&rdquo; (vertigo), ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast and/or irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, dizziness, lightheadedness or fainting on standing up, cold fingers and/or toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat tightness, nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting blood, or black tarry stools (faeces), gastroenteritis, burping, difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver that may cause abdominal pain and yellowing of the skin or whites of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle tightness, muscle twitching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty or inability to pass urine, difficulty to start urinating, needing to pass urine during the night, needing to pass more urine than normal, having a decreased urine flow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal vaginal bleeding, abnormal periods, including heavy, painful, irregular or prolonged, periods, unusually light or missed periods, pain in the testicles or scrotum</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, feeling cold, thirst, shivering, feeling hot, abnormal gait</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cymbalta may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol</p><p><strong>Rare side effects </strong><strong>(may affect up to 1 in 1000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction which causes difficulty in breathing or dizziness with swollen tongue or lips, allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased thyroid gland activity which can cause tiredness or weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration, low levels of sodium in the blood (mostly in elderly people; the symptoms may include feeling dizzy, weak, confused, sleepy or very tired, or feeling or being sick, more serious symptoms are fainting, fits or falls), syndrome of inappropriate secretion of anti-diuretic hormone (SIADH)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal behaviour, mania (over activity, racing thoughts and decreased need for sleep), hallucinations, aggression and anger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;Serotonin syndrome&rdquo; (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure in the eye (glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing, wheezing and shortness of breath which may be accompanied by a high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth, passing bright red blood in your stools, bad breath, inflammation of the large intestine (leading to diarrhoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, yellowing of the skin or whites of the eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (serious illness with blistering of the skin, mouth, eyes and genitals), serious allergic reaction which causes swelling of the face or throat (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; contraction of the jaw muscle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal urine odour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menopausal symptoms, abnormal production of breast milk in men or women</p><p>&middot;&nbsp;&nbsp; excessive vaginal bleeding shortly after birth (postpartum haemorrhage)</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><p>&middot;&nbsp;&nbsp; inflammation of the blood vessels in the skin (cutaneous vasculitis)</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.<strong> </strong>You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine out of the sight and reach of children.</strong></p><p>Do not use this medicine after the expiry date which is stated on the carton.</p><p>Store in the original package to protect from moisture. Store below 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The <strong>active</strong> substance is duloxetine.</p><p>Each capsule contains 60 mg of duloxetine (as hydrochloride).</p><p>The <strong>other</strong> ingredients are:</p><p><em>Capsule content</em>: hypromellose, hypromellose acetate succinate, sucrose, sugar spheres, talc, titanium dioxide (E171), triethyl citrate <em>(See end of section 2 for further information on sucrose).</em></p><p><em>Capsule shell:</em> gelatin, sodium lauryl sulfate, titanium dioxide (E171), indigo carmine (E132), yellow iron oxide (E172) (60&nbsp;mg only) and edible green ink (30&nbsp;mg) or edible white ink (60&nbsp;mg).</p><p><em>Edible green ink:</em> synthetic black iron oxide (E172), synthetic yellow iron oxide (E172), propylene glycol, shellac.</p><p><em>Edible white ink</em>: titanium dioxide (E171), propylene glycol, shellac, povidone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cymbalta is a hard gastro-resistant capsule. Each capsule of Cymbalta contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.  

Cymbalta is available in 2 strengths: 30 mg and 60 mg.
The 30 mg capsules are blue and white and are printed with ‘30 mg’ and the code ‘9543’.
The 60 mg capsules are blue and green and are printed with ‘60 mg’ and the code ‘9542’.

Cymbalta 60 mg is available in packs of 28, 56, 84, and 98 hard gastro-resistant capsules and in multipacks containing 100 (5 packs of 20) and 500 (25 packs of 20) hard gastro-resistant capsules.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.</p><p>Manufacturer:<strong> </strong></p><p>Lilly Del Caribe</p><p>Puerto Rico Industrial Park, 12.6 KM 65th Infantry Road, Carolina, Puerto Rico 00985</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company- Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2020
Version 6
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سيمبالتا على المادة الفعالة ديلوكسيتين. يساعد سيمبالتا في زيادة مستوى السيروتونين والنورأدرينالين في الجهاز العصبي.</p><p>يستخدم سيمبالتا لدى البالغين لعلاج:</p><p>- اضطراب الإكتئاب الحاد.</p><p>- ألم اعتلال الأعصاب الطرفية السكري. (عادة ما توصف بأنها مثل شعور بالحرق، شعور بالطعن، الوخز، أو آلام منطلقة نارية أو حكة أو مثل صدمة كهربائية. قد يكون هناك فقدان الإحساس في المنطقة المصابة، أو الإحساس بالألم نتيجة اللمس أو الحرارة أو البرودة أو الضغط).</p><p>يبدأ مفعول سيمبالتا لدى معظم مرضى الإكتئاب أو القلق في غضون أسبوعين من بداية العلاج، ولكنه قد يستغرق من أسبوعين إلى 4 أسابيع قبل شعور المريض بتحسن. ينبغي عليك إخبار طبيبك في حالة عدم الشعور بتحسن بعد مرور هذه المدة. يمكن أن يستمر طبيبك في وصف سيمبالتا لك حتى بعد شعورك بتحسن، وهذا للوقاية من عودة الإكتئاب أو القلق.</p><p>لدى مرضى ألم اعتلال الأعصاب الطرفية السكري، قد يستغرق المريض عدة أسابيع قبل الشعور بتحسن. ينبغي عليك استشارة طبيبك في حالة عدم الشعور بتحسن بعد شهرين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم تناول سيمبالتا إذا كنت تعاني من:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط حساسية لمادة الديلوكسيتين أو &nbsp;أي من المكونات الأخرى لهذا الدواء (انظر القسم 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الكبد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كلوي شديد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول، أو تناولت خلال الأربعة عشر يوما السابقة، دواء آخر يعرف بمثبط الإنزيم المؤكسد لأحادي الأمين (انظر القسم &quot;أدوية أخرى وسيمبالتا&quot;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول فلوفوكسامين، والذي عادة ما يستخدم في علاج الإكتئاب، أو سيبروفلوكساسين أو إنوكساسين اللذين يُستخدمان لعلاج بعض الأنواع من العدوى.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تحتوي على مادة ديلوكسيتين (انظر القسم &quot;أدوية أخرى وسيمبالتا&quot;).</p><p>يرجى إبلاغ طبيبك إذا كنت تعاني من ارتفاع ضغط الدم أو من مرض قلبي، حيث سيقرر طبيبك ما إذا كان يجب أن تتناول سيمبالتا.</p><p><strong>تحذيرات واحتياطات:</strong></p><p>توجد بعض الأسباب التي قد تجعل دواء سيمبالتا غير ملائم لحالتك، لذا ينبغي إبلاغ طبيبك قبل تناول سيمبالتا إذا كنت تعاني من أيٍ من الحالات التالية:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى لعلاج الإكتئاب (انظر القسم &quot;أدوية أخرى وسيمبالتا&quot;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول نبتة القديس يوحنا (سانت جونز) المثقبة (هايبيريكم بيرفراتم - العرن المثقوب)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلوي.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نوبات صرع.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بداء الهوس.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب ثنائي القطب.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في العينين؛ كبعض الأنواع من الجلوكوما (ارتفاع الضغط في العين).إذا كنت تعاني في السابق من اضطرابات النزيف (زيادة القابلية لتكوين كدمات) بشكل خاص إذا كنتِ حاملاً (راجعي فقرة &quot;الحمل والإرضاع&quot;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عرضة لانخفاض مستوى الصوديوم بالدم (كما هو الحال عند تناول مدرات البول، خصوصًا لدى كبار السن).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليا دواء آخر قد يؤدي إلى تلف الكبد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تحتوي على مادة ديلوكسيتين (انظر قسم &quot;أدوية أخرى وسيمبالتا&quot;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو تخططين للحمل، سيمبالتا قد يضر مولودك. تحدثى إلى مقدم الرعاية الصحية الخاص بك عن الخطر الذي قد يتعرض له مولودك إذا كنت تتناولين سيمبالتا أثناء الحمل.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية على الفور إذا كنت حاملاً أو تعتقدين أنك حامل أثناء العلاج بسيمبالتا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ترضعين أو تخططين للرضاعة الطبيعية، فإن سيمبالتا يمر في حليب الثدي وقد يضر طفلك. تحدثي إلى مقدم الرعاية الصحية الخاص بك عن أفضل طريقة لإطعام طفلك أثناء تناول سيمبالتا.</p><p>قد يؤدي تناول سيمبالتا إلى الشعور بالأرق أو عدم القدرة على الجلوس أو الوقوف باستقرار. ينبغي إبلاغ طبيبك إذا شعرت بمثل هذه الأعراض.</p><p>يمكن أن تسبّب الأدوية مثل سيمبالتا (المسمّاة المثبّطات الإنتقائيّة لإعادة قبط السيروتونين / مثبّطات إعادة قبط السيروتونين والنورأدرينالين) عوارض عجز جنسيّ (راجع القسم 4). في بعض الحالات، استمرّت هذه العوارض بعد إيقاف العلاج.</p><p><strong><em>الأفكار الإنتحارية و</em></strong><strong><em> </em></strong><strong><em>تفاقم حالة الإكتئاب أو القلق</em></strong></p><p>إذا كنت تعاني من الإكتئاب و/أو اضطرابات القلق، فقد تراودك أحيانًا أفكار لإلحاق الضرر بنفسك أو قتل نفسك. و قد تزداد هذه الأفكار عند البدء في تناول مضادات الإكتئاب، حيث إن هذه الأدوية تستغرق وقتًا لظهور مفعولها، عادة أسبوعين، وفي بعض الأحيان فترات أطول من ذلك.&nbsp;&nbsp;&nbsp;</p><p>قد تكون أكثر عرضة لهذه الأفكار إذا كنت تعاني من:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راودتك مسبقا أفكار إلحاق الأذى بنفسك أو قتل نفسك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في سن الشباب، حيث أوضحت المعلومات الناتجة عن التجارب السريرية ارتفاع خطر السلوك الإنتحاري وسط الشباب الأقل من 25 عاما الذين يعانون من اضطرابات نفسية وكانوا يُعالجون بمضادات الإكتئاب.</p><p><strong>إذا راودتك أفكار لإلحاق الضرر بنفسك أو قتل نفسك</strong><strong> </strong><strong>في أي وقت، فاتصل بطبيبك أو توجه إلى أقرب مستشفى فورًا.</strong></p><p>يمكن أن يساعدك إخبار أحد أقربائك أو أصدقائك المقربين أنك تعاني من الإكتئاب أو اضطراب القلق، و الطلب منهم قراءة هذه النشرة. ويمكنك أيضا سؤالهم ما إذا كانوا يلاحظون تدهور حالة الإكتئاب أو القلق لديك أو كانوا قلقين بشأن ظهور أية تغيرات سلوكية عليك.</p><p><strong><em>الأطفال والمراهقون أقل من </em></strong><strong><em>18</em></strong><strong><em> سنة</em></strong></p><p>يجب عدم استخدام سيمبالتا لدى الأطفال والمراهقين الأقل من 18 عاما. كما ينبغي أن تعرف أن المرضى الأقل من 18 عامًا يكونون أكثر عرضة للأعراض الجانبية كمحاولات الإنتحار و الأفكار الإنتحارية و العدوانية (غالبًا ما يظهر عليهم عدوانية وسلوك معارض وغضب)، وذلك عند تناول هذه المجموعة من الأدوية. وبالرغم من ذلك، فإن الطبيب قد يصف سيمبالتا للمرضى الأقل من 18 عام إذا قرر أن ذلك سيكون في مصلحة المريض. إذا وصف الطبيب سيمبالتا لمريض عمره أقل من 18 سنة، وأردتَ مناقشة ذلك، فيُرجى الرجوع إلى طبيبك. كما ينبغي عليك إبلاغ طبيبك إذا لاحظت ظهور أيٍ من الأعراض الجانبية المذكورة أعلاه أو تفاقمها لدى المرضى الذين تقل أعمارهم عن 18 سنة ويتناولون دواء سيمبالتا. إضافةً إلى ذلك، لم تثبت حتى الآن سلامة استخدام هذا الدواء على المدى الطويل فيما يتعلق بالنمو والنضج والنمو المعرفي والسلوكي لدى هذه الفئة العمرية من المرضى.</p><p><strong>أدوية أخرى وسيمبالتا</strong></p><p>&nbsp;يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو يمكن أن تتناول أية أدوية أخرى، بما في ذلك الأدوية التي تؤخذ بدون وصفة طبية.</p><p>يستخدم المكون الأساسي لسيمبالتا - مادة ديلوكسيتين - في أدوية أخرى لعلاج حالات أخرى مثل:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأعصاب السكري والإكتئاب والقلق وسلس البول.</p><p>ينبغي تجنب استخدام أكثر من دواء واحد من هذه الأدوية في وقت واحد. استشر طبيبك للتأكد من عدم تناول أدوية أخرى تحتوي على مادة ديلوكسيتين.</p><p>سيحدد طبيبك ما إذا كان بإمكانك تناول سيمبالتا مع أدوية أخرى. لذا، <strong>يجب ألا تبدأ أو تتوقف عن تناول أية أدوية - بما في ذلك الأدوية التي تؤخذ بدون وصفة طبية أو العلاجات العشبية &ndash; إلا بعد استشارة طبيبك. </strong></p><p>ينبغي عليك أيضا إخبار طبيبك إذا كنت تتناول أيًا من الأدوية التالية:</p><p><strong><em>مثبطات الإنزيم المؤكسد لأحادي الأمين: </em></strong>يجب عدم تناول سيمبالتا إذا كنت تتناول حاليًا - أو قد تناولت مؤخرًا (خلال الأربعة عشر يوما الماضية) دواء آخر مضادًا للإكتئاب يُسمى مثبط الإنزيم المؤكسد لأحادي الأمين. من أمثلة هذه الأدوية: موكلوبيميد (مضاد للإكتئاب) و لينيزوليد (مضاد حيوي). قد يؤدي تناول دواء من هذه الفئة مع العديد من الأدوية الأخرى - بما في ذلك عقار سيمبالتا - إلى حدوث أعراض جانبية خطيرة أو مهددة للحياة. يجب الانتظار 14 يومًا على الأقل بعد التوقف عن تناول مثبطات الإنزيم المؤكسد لأحادي الأمين قبل أن تبدأ في تناول سيمبالتا. كما ينبغي الانتظار 5 أيام على الأقل بعد التوقف عن تناول سيمبالتا قبل أن تبدأ في تناول مثبطات الإنزيم المؤكسد لأحادي الأمين.</p><p><strong><em>الأدوية</em></strong><strong><em> </em></strong><strong><em>المسببة للنعاس:</em></strong><em> </em>تتضمن هذه العقاقير الأدوية التي يصفها طبيبك وهي محتوية على مركبات بنزوديازيبين ومسكنات الألم القوية ومضادات الذهان ومركبات فينوباربيتال و مضادات الهيستامين.</p><p><strong><em>الأدوية</em></strong><strong><em> </em></strong><strong><em>المحفزة لإفراز السيروتونين:</em></strong><strong><em> </em></strong>تريبتان وترامادول وتريبتوفان ومثبطات امتصاص السيروتونين الإنتقائية (مثل باروكزيتين وفلوكزيتين) ومثبطات امتصاص نورابينيفرين- السيروتونين (مثل فينلافاكسين) ومضادات الاكتئاب ثلاثية الحلقات (مثل كلوميبرامين وأميتريبتيلين) وعقار بيثيدين ونبتة سانت جونز (القديس يوحنا) ومثبطات أكسيداز أحادي الأمين (مثل موكلوبيميد ولينيزوليد). قد تزيد هذه الأدوية من معدل حدوث الأعراض الجانبية، لذا عليك أن تقوم باستشارة طبيبك فور شعورك بأية أعراض غير طبيعية أثناء تناولك أيًا من هذه الأدوية بجانب عقار سيمبالتا.</p><p><strong><em>مضادات التخثر الفموية:</em></strong> تقوم هذه الأدوية بزيادة سيولة الدم، أو منع الدم من التخثر. وقد تجعلك أكثر عرضة للنزيف.</p><p><strong>تناول سيمبالتا مع الطعام</strong>، <strong>الشراب والكحول</strong></p><p>يمكنك تناول سيمبالتا مع الطعام أو بدونه، يجب توخي الحذر عند تناول الكحول أثناء العلاج بسيمبالتا.</p><p><strong>الحمل و</strong><strong> </strong><strong>الرضاعة الطبيعية</strong></p><p>يجب استشارة طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً أو ترضعين، أو تظنين أنك حامل أو تنوين الإنجاب.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يجب عليك إخبار طبيبك المعالج إذا كنت حاملاً أو إذا كنت تنوين ذلك، أثناء تناولك لسيمبالتا. ينبغي عدم البدء في تناول الدواء إلا بعد مناقشة الفوائد والمخاطر المحتملة لسيمبالتا على الجنين مع طبيبك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الحرص على إخبار القابلة و/أو الطبيب بأنك تتناولين سيمبالتا، وذلك لإن تناول العقاقير المشابهة أثناء الحمل (مثبطات امتصاص السيروتونين الإنتقائية) قد يزيد من خطر تعرض المولود لحالة خطرة تعرف بارتفاع ضغط الدم الرئوي المستمر، مما يجعله يتنفس بسرعة وتظهر عليه زرقة. وعادة تبدأ هذه الأعراض في الظهور خلال الأربع وعشرين ساعة الأولى من الولادة. إذا حدثت هذه الأعراض لطفلك، فينبغي استشارة الطبيب أو القابلة فورًا.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما أن تناول سيمبالتا قرب نهاية الحمل قد يعرض الطفل لبعض الأعراض عند الولادة. عادةً تحدث هذه الأعراض عند الولادة أو خلال الأيام القليلة بعدها. يمكن أن تشمل هذه الأعراض ارتخاء العضلات ورعشة وهياج وضعف بالرضاعة واضطرابات بالتنفس وتشنجات. إذا لاحظت ظهور أيٍ من هذه الأعراض على طفلك أو انتابك القلق على سلامته، فينبغي استشارة الطبيب أو القابلة للحصول على المشورة اللازمة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تأخذين سيمبالتا في نهاية فترة الحمل، يزداد خطر تعرّضك لنزيف مهبليّ مفرط بعد الولادة بوقت قصير، بخاصة إذا كان لديك سوابق اضطرابات نزفيّة. يجب إعلام الطبيب أو القابلة بأنّك تأخذين الدولوكسيتين لكي يتمكّن/تتمكّن من إعطائك النصائح المناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يظهر من خلال البيانات المتاحة أن استخدام سيمبالتا خلال الأشهر الثلاثة الأولى من الحمل يساهم في زيادة خطر حدوث عيوب خلقية بصفة عامة لدى الطفل. إذا تم أخذ سيمبالتا خلال النصف الثاني من الحمل، فقد يكون هناك خطر متزايد من أن يولد الرضيع مبكرًا (6 أطفال خدج إضافيين لكل 100 امرأة يأخذن سيمبالتا في النصف الثاني من الحمل)، في الغالب بين الأسبوعين 35 و 36 من الحمل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك إخبار طبيبك إذا كنت تُرضِعين، حيث إنه لا يُنصح باستخدام سيمبالتا أثناء الرضاعة الطبيعية. يرجى استشارة الطبيب أو الصيدلي لمزيد من المعلومات.</p><p><strong>قيادة المركبات واستخدام الآلات</strong></p><p>قد يجعلك سيمبالتا تشعر بالنعاس أو الدوخة، لذا ينبغي عدم قيادة مركبات أو استخدام آلات حتى تتعرف على كيفية تأثير سيمبالتا عليك.&nbsp;</p><p><strong>يحتوي سيمبالتا</strong><strong> </strong><strong>على السكروز</strong></p><p>يحتوي سيمبالتا على <strong>السكروز</strong>. لذا، إذا كان أحد الأطباء المتخصصين أخبرك أنك تعاني من عدم تحمل بعض أنواع السكريات، فعليك استشارة الطبيب قبل تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي سيمبالتا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملجم) لكل كبسولة، وهذا يعني بشكل أساسي أنه &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ينبغي تناول هذا الدواء تماماً حسب وصفة طبيبك أو الصيدلي. وينبغي مراجعة طبيبك أو الصيدلي في حالة عدم التأكد من كيفية التناول.</p><p>يُتناول سيمبالتا عن طريق الفم. ينبغي بلع الكبسولة بكاملها مع بعض الماء.</p><p><em>لعلاج الإكتئاب و</em><em> </em><em>ألم الأعصاب السكري:</em></p><p>الجرعة المعتادة هي كبسولة واحدة 60 ملجم مرة واحدة في اليوم، إلا أن طبيبك قد يصف لك جرعة مختلفة تناسب حالتك.</p><p>لمساعدتك على تذكر جرعة سيمبالتا، يُنصح بتناول الدواء في نفس الموعد كل يوم.</p><p>يمكنك مناقشة طبيبك بشأن مدة العلاج بسيمبالتا. ولا تتوقف عن تناول سيمبالتا أو تغير جرعتك دون الرجوع إلى طبيبك. إن معالجة الإضطراب الذي تعاني منه بطريقة صحيحة أمر مهم لمساعدتك على التحسن. وإذا لم يُعالج الإضطراب كما يجب، فقد لا تشفى منه وقد تزداد الخطورة والصعوبة في المعالجة.</p><p><strong>إذا تناولت جرعة أكبر من الجرعة الموصوفة من سيمبالتا</strong></p><p>اتصل بطبيبك أو الصيدلي على الفور في حالة تناول جرعة أكبر من التي وصفها لك الطبيب من سيمبالتا. تشمل أعراض تناول جرعة مفرطة حدوث نعاس أو غيبوبة أو متلازمة السيروتونين (وهي تفاعل نادر قد يتسبب في الشعور بسعادة بالغة أو دوخة أو ارتباك حركي أو أرق أو شعور بالسكر أو حمى أو عرق أو تصلب بالعضلات) وتشنجات وقيء وسرعة نبض القلب.</p><p><strong>إذا نسيت تناول جرعة سيمبالتا</strong></p><p>إذا نسيت أن تتناول الجرعة، فعليك أن تتناولها بمجرد تذكرها. وإذا تذكرت الجرعة قرب موعد الجرعة التالية، فاترك هذه الجرعة وتناول جرعتك التالية في موعدها المعتاد. لا تتناول جرعة مزدوجة لتعويض الجرعة الفائتة. ولا تتناول أكثر من الجرعة اليومية الكلية التي وصفها لك الطبيب في اليوم الواحد.</p><p><strong>إذا توقفت عن تناول سيمبالتا</strong></p><p>لا تتوقف عن تناول الكبسولات دون الرجوع إلى طبيبك، حتى وإن كنت تشعر بتحسن حالتك. فإذا قرر طبيبك أنك لم تعد تحتاج إلى الاستمرار في تناول سيمبالتا، فسوف يطلب منك خفض الجرعة تدريجيًا على مدار أسبوعين على الأقل قبل التوقف عن العلاج كليًا.</p><p>تعرض بعض المرضى الذين توقفوا بشكل مفاجئ عن تناول سيمبالتا لحدوث بعض الأعراض مثل:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة و إحساس مثل وخز الإبر أو إحساس يشبه الإصابة بصدمة كهربائية (وخاصة في الرأس)، واضطرابات النوم (أحلام مزعجة وكوابيس وعدم القدرة على النوم) التعب والنعاس والشعور بالأرق أو الهياج، والشعور بالقلق والغثيان والقيء والرعشة والصداع وآلام في العضلات والانفعال والإسهال وفرط العرق أو الدوار.</p><p>عادة ما لا تكون هذه الأعراض خطيرة وتزول خلال عدة أيام، ولكن إذا شعرت بالانزعاج منها، فينبغي استشارة الطبيب.</p><p>لمزيد من الاستفسار عن استخدام هذا الدواء، يرجى الرجوع إلى الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية الأخرى، قد يتسبب هذا الدواء في حدوث بعض الأعراض الجانبية، إلا أنها لا تظهر في جميع المرضى. وعادة ما تكون هذه الأعراض من خفيفة إلى متوسطة الشدة وتزول خلال عدة أسابيع.</p><p><strong>الآثار الجانبية الشائعة جدا (يمكن أن تؤثر في أكثر من شخص واحد من كل </strong><strong>10</strong><strong> أشخاص) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع وشعور بالنعاس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وجفاف الفم</p><p><strong>الآثار الجانبية الشائعة (تؤثر في شخص واحد من كل </strong><strong>10</strong><strong> أشخاص) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم، الشعور بالهياج، ضعف الرغبة الجنسية، قلق، صعوبة أو فشل في الوصول للنشوة الجنسية، أحلام مزعجة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، لامبالاة، رعشة، شعور بالخدر، بما في ذلك الشعور بوخز إبر في الجلد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين بالأذن (سماع صوت في الأذن رغم عدم وجوده في المحيط الخارجي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بخفقان القلب في الصدر.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، تورد الوجه.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة التثاؤب.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، إسهال، ألم في المعدة، قيء، شعور بحرقة القلب أو عسر الهضم، ريح.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة العرق، طفح جلدي (مصحوب بحكة).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام وتشنج بالعضلات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول مؤلم، كثرة التبول.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الإنتصاب وتغيرات في القذف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء (غالبًا في كبار السن)، تعب.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p>لوحظ فقدان في الوزن لدى الأطفال والمراهقين تحت سن 18 سنة المصابين باكتئاب وعولجوا بهذا الدواء عندما بدأوا في استخدامه لأول مرة، ثم ازداد الوزن إلى معدله المناسب كالأطفال والمراهقين من نفس السن والجنس بعد 6 أشهر.</p><p><strong>الآثار الجانبية غير الشائعة (تؤثر في شخص واحد من كل </strong><strong>&nbsp;</strong><strong>100</strong><strong>شخص) </strong></p><p>التهاب في الحلق يسبب خشونة في الصوت</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية، صعوبة في النوم، وطحن أو انقباض الأسنان، والشعور بالضياع وفقد الصواب، فقدان وجود الحافز</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهزات المفاجئة اللاإرادية أو تشنجات للعضلات والإحساس بالأرق أو عدم القدرة على الجلوس أو الوقوف، والشعور بالتوتر، وصعوبة التركيز، والتغيرات في حاسة التذوق، وصعوبة السيطرة في الحركة على سبيل المثال عدم وجود تنسيق أو حركات لا إرادية للعضلات، متلازمة تململ الساقين، وسوء نوعية النوم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبر في حجم بؤبؤ العين (الجزء المظلم في العين)، ومشاكل في البصر</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو &quot;الغزل&quot; (الدوار)، وألم الأذن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة و / أو عدم انتظام ضربات القلب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، والدوخة، والدوار أو الإغماء عند الوقوف وأصابع و/ أو أصابع القدم باردة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الحلق، ونزيف في الأنف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ بالدم، أو براز أسود قاري، التهاب المعدة و الأمعاء، التجشؤ، وصعوبة في البلع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الذي قد يؤدي إلى آلام في البطن واصفرار الجلد أو بياض العينين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق في الليل، قشعريرة، العرق البارد، والحساسية لأشعة الشمس، سهولة ظهور الكدمات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمة في العضلات، وارتعاش العضلات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو عدم القدرة على التبول، وصعوبة بدء التبول، والحاجة إلى التبول أثناء الليل، زيادة نسبة التبول أكثر من المعتاد، وانخفاض تدفق البول.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبلي غير طبيعي، وفترات حيض غير طبيعية، بما في ذلك الثقيلة، والمؤلمة، وغير المنتظمة وتمتد لفترات طويلة، وفترات حيض غير طبيعية خفيفة أو منعدمة، ألم في الخصيتين أو الصفن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلم في الصدر، الشعور بالبرد، والعطش، والارتعاش، والشعور بالحرّ، ومشية غير طبيعية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الوزن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب سيمبالتا آثاراً قد لا تكون على علم بها، مثل زيادة في إنزيمات الكبد أو مستويات البوتاسيوم في الدم، والكرياتين فسفوكيناز، السكر، أو الكولسترول</p><p><strong>الآثار الجانبية النادرة (تؤثر في شخص واحد من كل</strong><strong>1000 </strong><strong>&nbsp;شخص)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية شديدة مسببة لصعوبة في التنفس أو دوار مع تورم اللسان أو الشفاه، وأمراض الحساسية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدرقية الذي يمكن أن يسبب التعب أو زيادة الوزن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف، وانخفاض مستويات الصوديوم في الدم (ومعظم الحالات في كبار السن، ويمكن أن تشمل الأعراض الشعور بالدوار، والضعف، والشعور بالإرتباك، الشعور بالنعاس أو التعب المفرط، الشعور بالمرض أو أن تكون مريضا، وأكثر الأعراض خطورة هي الإغماء، نوبات أو السقوط)، و متلازمة الإفراز غير الملائم لهرمون إدرار البول (SIADH).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلوك الانتحاري، والهوس (زيادة في النشاط، تسابق في الأفكار وانخفاض الحاجة إلى النوم)، والهلوسة، والعدوان والغضب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة السيروتونين &quot;(رد فعل نادر الذي قد يسبب مشاعر سعادة كبيرة، والنعاس، والارتباك، والأرق، والشعور بحالة سكر، والحمى، والتعرق أو عضلات صلبة)، نوبات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط العين (الجلوكوما).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال والصفير وضيق التنفس الذي قد يكون مصحوبا بدرجة حرارة عالية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم، خروج دم أحمر غاني في البراز، وسوء التنفس، والتهاب الأمعاء الغليظة (مما يؤدي إلى الإسهال)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد، و اصفرار الجلد أو بياض العينين (اليرقان).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون (مرض خطير مع ظهور تقرحات في الجلد والفم والعينين والأعضاء التناسلية)، حساسية حادة تؤدي إلى تورم في الوجه أو الحلق (وذمة وعائية)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص عضلات الفك</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رائحة في البول غير طبيعية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أعراض سن اليأس، والإنتاج غير الطبيعي من حليب الثدي لدى الرجال والنساء</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبليّ مفرط بعد الولادة بوقت قصير (نزيف ما بعد الولادة)</p><p><strong>آثار جانبية نادرة جدا (تؤثر في شخص واحد من كل </strong><strong>10000</strong><strong> شخص)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في الجلد (الأوعية الدموية الجلدية)</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا شعرت بأيّ تأثير جانبيّ، أعلم طبيبك أو الصيدلي. ينطبق هذا على كل تأثير جانبي محتمل غير مذكور في هذه النشرة. يمكنك أيضًا التبليغ عن الآثار الجانبيّة مباشرة عبر نظام الإبلاغ الوطني<strong> </strong>المذكور في المقطع 6. بالتبليغ عن الآثار الجانبيّة، تساهم في تزويد معلومات إضافية حول سلامة الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>احفظ هذا</strong><strong> </strong><strong>الدواء بعيدا عن مرأى</strong><strong> </strong><strong>ومتناول الأطفال.</strong></p><p>لا تستخدم سيمبالتا بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p><p>قم بحفظ<strong> </strong>هذا الدواء في علبته الأصلية لحفظه من الرطوبة. يحفظ في درجة حرارة أقل من 30 درجة مئوية.&nbsp;</p><p>لا ينبغي التخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. عليك الرجوع إلى الصيدلي لمعرفة كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على الحفاظ على البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة <strong>الفعالة</strong> هي ديلوكسيتين.</p><p>تحتوي كل كبسولة على 60 ملجم من ديلوكسيتين (في صورة هيدروكلوريد).</p><p>وتشمل المكونات <strong>الأخرى</strong> ما يلي:</p><p><em>مكونات الكبسولة:</em><em> </em>هيبروميللوز، خلات ساكسينات الهيبروميللوز، سكروز، كرات السكر، طلق، ثاني أكسيد التيتانيوم (E171)، سترات ثلاثي الإيثيل، <em>(انظر نهاية القسم رقم </em><em>2</em><em> لمزيد من المعلومات عن السكروز)</em>.</p><p><em>غلاف الكبسولة:</em><em> </em>جيلاتين، سلفات الصوديوم لوريل، ثاني أكسيد التيتانيوم (E171)، صبغة القرمز النيلي (إنديجو كارمن) (E132)، أكسيد حديد أصفر (E172) (60 ملجم فقط)، وحبر أخضر مستساغ (30 ملجم) أو حبر أبيض مستساغ (60 ملجم).</p><p><em>الحبر الأخضر المستساغ:</em> أكسيد الحديد الأسود الصناعي (E172)، أكسيد الحديد الأصفر الصناعي (E172)، بروبولين جليكول، شيلاك.</p><p><em>الحبر الأبيض المستساغ:</em> ثاني أكسيد التيتانيوم (E171)، بروبولين جليكول، شيلاك، بوفيدون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر سيمبالتا على شكل كبسولات صلبة مقاومة لعصارة المعدة. وتحتوي كل كبسولة على كريات من مادة هيدروكلوريد الديلوكسيتين مغلفة لحمايتها من حموضة المعدة.&nbsp;</p><p>ويتوفر سيمبالتا في تركيزين: 30 ملجم و60 ملجم.</p><p>كبسولات سيمبالتا 30 ملجم تكون باللون الأزرق والأبيض ومطبوع عليها &quot;30 mg&quot; والكود &quot;9543&quot;.</p><p>كبسولات سيمبالتا 60 ملجم تكون باللون الأزرق والأخضر ومطبوع عليها &quot;60 mg&quot; والكود &quot;9542&quot;.</p><p>سيمبالتا 60 ملجم متاح في علب من 28، 56، 84 و 98كبسولة صلبة مقاومة لتأثير المعدة، وفي علب متعدّدة تحتوي على100 &nbsp;&nbsp;5)علب من (20 &nbsp;و500 &nbsp;25)علبة من (20 كبسولة صلبة مقاومة لتأثير المعدة.</p><p>ليست جميع الأحجام مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب تفويض التسويق:</p><p>إيلي ليلي ندرلاند &nbsp;&nbsp;B.V.بابندوربسوغ 83، 3528، &nbsp;BJأوتركت، هولندا.</p><p>الشركة المصنعة:</p><p>ليلي دل كريبي. منطقة بورتوريكو الصناعية 12,6 كلم 65 طريق انفنتري. كارولينا، بورتوريكو 00985.</p><p>للحصول على أيّ معلومات تتعلّق بهذا الدواء، يُرجى الاتصال بالممثل المحلّي لحامل رخصة التسويق:</p><p>إيلي ليلي وشركاه - المملكة العربية السعودية</p><p>صندوق البريد 92120</p><p>الطابق 16، مبنى رقم 3074،</p><p>برج ب، أبراج العُليَّا</p><p>شارع الأمير محمد بن عبد العزيز</p><p>العُليَّا، الرياض</p><p>المملكة العربية السعودية</p><p>الخط المباشر: 966114617800+، 96611461785+</p><p>الفاكس: 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو  2020 
النسخة  7 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cymbalta 60 mg hard gastro-resistant capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each capsule contains 60 mg of duloxetine (as hydrochloride).

Excipient(s) with known effect
Each capsule may contain up to 111 mg sucrose.

For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hard gastro-resistant capsule.
Opaque green body, imprinted with ‘60 mg’ and an opaque blue cap, imprinted with ‘9542’.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp; Treatment of major Depressive Disorder.</p><p>&middot;&nbsp; Treatment of diabetic peripheral neuropathic pain.</p><p>Cymbalta is indicated in adults.</p><p>For further information see section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Major depressive disorder</em></p><p>The starting and recommended maintenance dose is 60 mg once daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day have been evaluated from a safety perspective in clinical trials. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations.</p><p>Therapeutic response is usually seen after 2-4 weeks of treatment.</p><p>After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse. In patients responding to duloxetine, and with a history of repeated episodes of major depression, further long-term treatment at a dose of 60 to 120 mg/day could be considered.</p><p><em>Diabetic peripheral neuropathic pain</em></p><p>The starting and recommended maintenance dose is 60&nbsp;mg daily with or without food. Dosages above 60&nbsp;mg once daily, up to a maximum dose of 120&nbsp;mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. The plasma concentration of duloxetine displays large inter-individual variability (see section 5.2). Hence, some patients that respond insufficiently to 60&nbsp;mg may benefit from a higher dose.</p><p>Response to treatment should be evaluated after 2 months. In patients with inadequate initial response, additional response after this time is unlikely.</p><p>The therapeutic benefit should be reassessed regularly (at least every three months) (see section 5.1).</p><p><em>Special populations</em></p><p><em>Elderly</em></p><p>No dosage adjustment is recommended for elderly patients solely on the basis of age. However, as with any medicine, caution should be exercised when treating the elderly, especially with Cymbalta 120 mg per day for major depressive disorder or generalised anxiety disorder, for which data are limited (see sections 4.4 and 5.2).</p><p><em>Hepatic impairment</em></p><p>Cymbalta must not be used in patients with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).</p><p><em>Renal impairment </em></p><p>No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min). Cymbalta must not be used in patients with severe renal impairment (creatinine clearance &lt;30 ml/min; see section 4.3).</p><p>Paediatric population</p><p>Duloxetine should not be used in children and adolescents under the age of 18 years for the treatment of major depressive disorder because of safety and efficacy concerns (see sections 4.4, 4.8 and 5.1).</p><p>The safety and efficacy of duloxetine for the treatment of generalised anxiety disorder in paediatric patients aged 7-17 years have not been established. Current available data are described in sections 4.8, 5.1 and 5.2.</p><p>The safety and efficacy of duloxetine for the treatment of diabetic peripheral neuropathic pain has not been studied. No data are available.</p><p><em>Discontinuation of treatment</em></p><p>Abrupt discontinuation should be avoided. When stopping treatment with Cymbalta the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><u>Method of administration</u></p><p>For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Concomitant use of Cymbalta with nonselective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated (see section 4.5).

Liver disease resulting in hepatic impairment (see section 5.2).

Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).

Severe renal impairment (creatinine clearance <30 ml/min) (see section 4.4).

The initiation of treatment with Cymbalta is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 4.8).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Mania and seizures</em></p><p>Cymbalta should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures.</p><p><em>Mydriasis</em></p><p>Mydriasis has been reported in association with duloxetine; therefore, caution should be used when prescribing Cymbalta to patients with increased intraocular pressure, or those at risk of acute narrow-angle glaucoma.</p><p><em>Blood pressure and heart rate</em></p><p>Duloxetine has been associated with an increase in blood pressure and clinically significant hypertension in some patients. This may be due to the noradrenergic effect of duloxetine. Cases of hypertensive crisis have been reported with duloxetine, especially in patients with pre-existing hypertension. Therefore, in patients with known hypertension and/or other cardiac disease, blood pressure monitoring is recommended, especially during the first month of treatment. Duloxetine should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure. Caution should also be exercised when duloxetine is used with medicinal products that may impair its metabolism (see section 4.5). For patients who experience a sustained increase in blood pressure while receiving duloxetine either dose reduction or gradual discontinuation should be considered (see section 4.8). In patients with uncontrolled hypertension duloxetine should not be initiated (see section 4.3).</p><p><em>Renal impairment</em></p><p>Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance &lt;30 ml/min). For patients with severe renal impairment, see section 4.3. See section 4.2 for information on patients with mild or moderate renal dysfunction.</p><p><em>Serotonin syndrome</em></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with duloxetine treatment, particularly with concomitant use of other serotonergic agents (including SSRIs, SNRIs tricyclic antidepressants or triptans), with agents that impair metabolism of serotonin such as MAOIs, or with antipsychotics or other dopamine antagonists that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).</p><p>If concomitant treatment with duloxetine and other serotonergic agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p><p><em>St John&rsquo;s wort</em></p><p>Adverse reactions may be more common during concomitant use of Cymbalta and herbal preparations containing St John&rsquo;s wort (Hypericum &nbsp;perforatum).</p><p><em>Suicide</em></p><p><em>Major Depressive Disorder </em><em>and Generalised Anxiety Disorder: </em>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which Cymbalta is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Cases of suicidal thoughts and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.8).</p><p>Close supervision of patients and in particular those at high risk should accompany medicinal product therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p><em>Diabetic Peripheral Neuropathic Pain: </em>As with other medicinal products with similar pharmacological action (antidepressants), isolated cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Concerning risk factors for suicidality in depression, see above. Physicians should encourage patients to report any distressing thoughts or feelings at any time.</p><p><em>Use in children and adolescents under 18 years of age</em></p><p>Cymbalta should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempts and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger), were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms (see section 5.1). In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking (see section 4.8).</p><p><em>Haemorrhage </em></p><p>There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs), including duloxetine. Duloxetine may increase the risk of postpartum haemorrhage (see section&nbsp;4.6). Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function (e.g. NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.</p><p>A post-marketing study showed a higher incidence of postpartum haemorrhage in mothers taking duloxetine.</p><p><em>Hyponatraemia</em></p><p>Hyponatraemia has been reported when administering Cymbalta, including cases with serum sodium lower than 110 mmol/l. Hyponatraemia may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients or patients treated with diuretics.</p><p><em>Discontinuation of treatment</em></p><p>Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with Cymbalta and 23% of patients taking placebo. The risk of withdrawal symptoms seen with SSRI&rsquo;s and SNRI&rsquo;s may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that duloxetine should be gradually tapered when discontinuing treatment over a period of no less than 2 weeks, according to the patient&rsquo;s needs (see section 4.2).</p><p><em>Elderly</em></p><p>Data on the use of Cymbalta 120 mg in elderly patients with major depressive disorder and generalised anxiety disorder are limited. Therefore, caution should be exercised when treating the elderly with the maximum dosage (see sections 4.2 and 5.2).</p><p><em>Akathisia/psychomotor restlessness</em></p><p>The use of duloxetine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><em>Medicinal products containing duloxetine</em></p><p>Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence). The use of more than one of these products concomitantly should be avoided.</p><p><em>Hepatitis/increased liver enzymes</em></p><p>Cases of liver injury, including<em> s</em>evere elevations of liver enzymes (&gt;10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8). Most of them occurred during the first months of treatment. The pattern of liver damage was predominantly hepatocellular.<em> </em>Duloxetine should be used with caution in patients treated with other medicinal products associated with hepatic injury.</p><p><em>Sexual dysfunction</em></p><p>Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRIs.</p><p><em>Sucrose</em></p><p>Cymbalta hard gastro-resistant capsules contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p><em>Sodium</em></p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Monoamine oxidase inhibitors (MAOIs): </em>Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping Cymbalta before starting an MAOI (see section 4.3).</p><p>The concomitant use of Cymbalta with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4). The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with Cymbalta &nbsp;(see section 4.4).</p><p><em>Inhibitors of CYP1A2: </em>Because CYP1A2 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine. Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUC<sub>o-t</sub> 6-fold. Therefore Cymbalta should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).</p><p><em>CNS medicinal products</em>: The risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section. Consequently, caution is advised when Cymbalta is taken in combination with other centrally acting medicinal products or substances including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).</p><p><em>Serotonergic agents: </em>In rare cases, serotonin syndrome has been reported in patients using SSRIs/ SNRIs &nbsp;concomitantly with serotonergic agents. Caution is advisable if Cymbalta is used concomitantly with serotonergic agents like SSRIs, SNRIs, tricyclic antidepressants&nbsp; like clomipramine or amitriptyline MAOIs like moclobemide or linezolid, St John&rsquo;s wort (Hypericum &nbsp;perforatum) or triptans, tramadol, pethidine and tryptophan&nbsp; (see section 4.4).</p><p><em>Effect of duloxetine on other medicinal products</em></p><p><em>Medicinal products metabolised by CYP1A2: </em>The pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily).</p><p><em>Medicinal products metabolised by CYP2D6:</em> Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended. Caution is advised if Cymbalta is co-administered with medicinal products that are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such as flecainide, propafenone and metoprolol).</p><p><em>Oral contraceptives and other steroidal agents: </em>Results of <em>in vitro </em>studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A. Specific <em>in vivo</em> drug interaction studies have not been performed.</p><p><em>Anticoagulants and antiplatelet agents: </em>Caution should be exercised when duloxetine is combined with oral anticoagulants or antiplatelet agents due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction. Furthermore, increases in INR values have been reported when duloxetine was co-administered to patients treated with warfarin. However, concomitant administration of duloxetine with warfarin under steady state conditions, in healthy volunteers, as part of a clinical pharmacology study, did not result in a clinically significant change in INR from baseline or in the pharmacokinetics of R- or S-warfarin.</p><p><em>Effects of other medicinal products on duloxetine</em></p><p><em>Antacids and H<sub>2</sub> antagonists: </em>Co-administration of duloxetine with aluminium- and magnesium-containing antacids or duloxetine with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.</p><p><em>Inducers of CYP1A2: </em>Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Fertility</em></p><p>In animal studies, duloxetine had no effect on male fertility, and effects in females were only evident at doses that caused maternal toxicity.</p><p><em>Pregnancy </em></p><p>Studies in animals have shown reproductive toxicity at systemic exposure levels (AUC) of duloxetine lower than the maximum clinical exposure (see section 5.3).</p><p>Two large observational studies do not suggest an overall increased risk of major congenital malformation (one from the US including 2,500 exposed to duloxetine during the first trimester and one from the EU including 1,500 exposed to duloxetine during the first trimester). The analysis on specific malformations such as cardiac malformations shows inconclusive results.</p><p>In the EU study, maternal exposure to duloxetine during late pregnancy (at any time from 20 weeks gestational age to delivery) was associated with an increased risk for preterm birth (less than 2-fold, corresponding to approximately 6 additional premature births per 100&nbsp;women treated with duloxetine late in pregnancy). The majority occurred between 35 and 36 weeks of gestation. This association was not seen in the US study.</p><p>The US observational data have provided evidence of an increased risk (less than 2‑fold) of postpartum haemorrhage following duloxetine exposure within the month prior to birth.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to SNRI treatment, this potential risk cannot be ruled out with duloxetine taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>As with other serotonergic medicinal products, discontinuation symptoms may occur in the neonate after maternal duloxetine use near term. Discontinuation symptoms seen with duloxetine may include hypotonia, tremor, jitteriness, feeding difficulty, respiratory distress and seizures. The majority of cases have occurred either at birth or within a few days of birth.</p><p>Cymbalta should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Women should be advised to notify their physician if they become pregnant, or intend to become pregnant, during therapy.</p><p>Data from a postmarketing retrospective cohort study indicate that use of duloxetine in the month before delivery may be associated with an increased risk of postpartum haemorrhage. Data from published literature and from a postmarketing retrospective cohort study have not identified a clear drug-associated risk of major birth defects or other adverse developmental outcomes (see Data). There are risks associated with untreated depression and fibromyalgia in pregnancy, and with exposure to SNRIs and SSRIs, including CYMBALTA, during pregnancy (see Clinical Considerations).</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p>Clinical Considerations</p><p>Disease-associated Maternal and/or Embryo/Fetal Risk</p><p>Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study that followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.</p><p>Pregnant women with fibromyalgia are at increased risk for adverse maternal and infant outcomes including preterm premature rupture of membranes, preterm birth, small for gestational age, intrauterine growth restriction, placental disruption, and venous thrombosis. It is not known if these adverse maternal and fetal outcomes are a direct result of fibromyalgia or other comorbid factors.</p><p>Maternal Adverse Reactions</p><p>Use of duloxetine in the month before delivery may be associated with an increased risk of postpartum haemorrhage</p><p>Data</p><p>Human Data</p><p>Data from a postmarketing retrospective claims-based cohort study found an increased risk for postpartum hemorrhage among 955 pregnant women exposed to duloxetine in the last month of pregnancy compared to 4,128,460 unexposed pregnant women (adjusted relative risk: 1.53; 95% CI: 1.08-2.18). The same study did not find a clinically meaningful increase in the risk for major birth defects in the comparison of 2532 women exposed to duloxetine in the first trimester of pregnancy to 1,284,827 unexposed women after adjusting for several confounders. Methodologic limitations include possible residual confounding, misclassification of exposure and outcomes, lack of direct measures of disease severity, and lack of information about alcohol use, nutrition, and over-the-counter medication exposures.</p><p><em>Breast feeding</em></p><p>Duloxetine is very weakly excreted into human milk based on a study of 6 lactating patients, who did not breast feed their children. The estimated daily infant dose on a mg/kg basis is approximately 0.14% of the maternal dose (see section 5.2). As the safety of duloxetine in infants is not known, the use of Cymbalta while breast-feeding is not recommended.</p><p>There are reports of sedation, poor feeding, and poor weight gain in infants exposed to duloxetine through breast milk (see Clinical Considerations). There are no data on the effect of duloxetine on milk production.</p><p>Clinical Considerations</p><p>Infants exposed to CYMBALTA should be monitored for sedation, poor feeding and poor weight gain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Cymbalta may be associated with sedation and dizziness. Patients should be instructed that if they experience sedation or dizziness they should avoid potentially hazardous tasks such as driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a. Summary of the safety profile</em></p><p>The most commonly reported adverse reactions in patients treated with Cymbalta were nausea, headache, dry mouth, somnolence, and dizziness. However, the majority of common adverse reactions were mild to moderate, they usually started early in therapy, and most tended to subside even as therapy was continued.</p><p><em>b. Tabulated summary of adverse reactions</em></p><p>Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials</p><p>Table 1: Adverse reactions</p><p>Frequency estimate: Very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><em>Infections and infestations</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Laryngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Hyper-sensitivity disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Endocrine disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypo-thyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased Appetite</p></td><td style="vertical-align:top"><p>Hyperglycaemia (reported especially in diabetic patients)</p></td><td style="vertical-align:top"><p>Dehydration</p><p>Hyponatraemia</p><p>SIADH<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia Agitation</p><p>Libido decreased</p><p>Anxiety</p><p>Orgasm abnormal</p><p>Abnormal dreams</p></td><td style="vertical-align:top"><p>Suicidal ideation<sup>5,7</sup></p><p>Sleep disorder</p><p>Bruxism</p><p>Disorientation</p><p>Apathy</p></td><td style="vertical-align:top"><p>Suicidal</p><p>behaviour<sup>5,7</sup></p><p>Mania</p><p>Hallucinations</p><p>Aggression and anger<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p><p>Somnolence</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Lethargy</p><p>Tremor</p><p>Paraesthesia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myoclonus</p><p>Akathisia<sup>7</sup></p><p>Nervousness</p><p>Disturbance in attention</p><p>Dysgeusia</p><p>Dyskinesia</p><p>Restless legs syndrome</p><p>Poor quality sleep</p></td><td style="vertical-align:top"><p>Serotonin syndrome<sup>6</sup></p><p>Convulsion<sup>1</sup></p><p>Psychomotor restlessness<sup>6</sup></p><p>Extra-pyramidal symptoms<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>Mydriasis</p><p>Visual impairment</p></td><td style="vertical-align:top"><p>Glaucoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus<sup>1 </sup></p></td><td style="vertical-align:top"><p>Vertigo</p><p>Ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Supra-ventricular arrhythmia, mainly atrial fibrillation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood pressure increase<sup>3</sup></p><p>Flushing</p></td><td style="vertical-align:top"><p>Syncope<sup>2</sup></p><p>Hypertension<sup>3,7</sup></p><p>Orthostatic hypotension<sup>2</sup></p><p>Peripheral coldness</p></td><td style="vertical-align:top"><p>Hypertensive crisis<sup>3,6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Yawning</p></td><td style="vertical-align:top"><p>Throat tightness</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Interstitial lung disease<sup>10</sup></p><p>Eosinophilic pneumonia<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Gastrointestinal disorders </em></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p><p>Dry mouth</p></td><td style="vertical-align:top"><p>Constipation Diarrhoea</p><p>Abdominal pain</p><p>Vomiting</p><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage<sup>7</sup></p><p>Gastroenteritis</p><p>Eructation</p><p>Gastritis</p><p>Dysphagia</p></td><td style="vertical-align:top"><p>Stomatitis</p><p>Haematochezia</p><p>Breath odour</p><p>Microscopic</p><p>colitis<sup>9</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Hepato-biliary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis<sup>3</sup></p><p>Elevated liver enzymes (ALT, AST, alkaline phosphatase)</p><p>Acute liver injury</p></td><td style="vertical-align:top"><p>Hepatic failure<sup>6</sup></p><p>Jaundice<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sweating increased</p><p>Rash</p></td><td style="vertical-align:top"><p>Night sweats</p><p>Urticaria</p><p>Dermatitis contact</p><p>Cold sweat</p><p>Photo-sensitivity reactions</p><p>Increased tendency to bruise</p></td><td style="vertical-align:top"><p>Stevens-Johnson Syndrome<sup>6</sup></p><p>Angio-neurotic oedema<sup>6</sup></p></td><td style="vertical-align:top"><p>Cutaneous vasculitis</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculo-skeletal pain</p><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Muscle tightness</p><p>Muscle twitching</p></td><td style="vertical-align:top"><p>Trismus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria</p><p>Pollakiuria</p></td><td style="vertical-align:top"><p>Urinary retention</p><p>Urinary hesitation</p><p>Nocturia</p><p>Polyuria</p><p>Urine flow decreased</p></td><td style="vertical-align:top"><p>Urine odour abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p><p>Ejaculation disorder</p><p>Ejaculation delayed</p></td><td style="vertical-align:top"><p>Gynaecological haemorrhage</p><p>Menstrual disorder</p><p>Sexual dysfunction</p><p>Testicular pain</p></td><td style="vertical-align:top"><p>Menopausal symptoms</p><p>Galactorrhoea</p><p>Hyperprolactinaemia</p><p>Postpartum haemorrhage<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Falls<sup>8</sup></p><p>Fatigue</p></td><td style="vertical-align:top"><p>Chest pain<sup>7</sup></p><p>Feeling abnormal</p><p>Feeling cold</p><p>Thirst</p><p>Chills</p><p>Malaise</p><p>Feeling hot</p><p>Gait disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>Weight increase</p><p>Blood creatine phosphokinase increased</p><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>Blood cholesterol increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1&nbsp; </sup>Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation.</p><p><sup>2&nbsp; </sup>Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment.</p><p><sup>3&nbsp; </sup>See section 4.4.</p><p><sup>4&nbsp; </sup>Cases of aggression and anger have been reported particularly early in treatment or after treatment discontinuation.</p><p><sup>5&nbsp; </sup>Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4).</p><p><sup>6</sup> Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials.</p><p><sup>7</sup> Not statistically significantly different from placebo.</p><p><sup>8</sup> Falls were more common in the elderly (<em>&ge;</em>65 years old).</p><p><sup>9</sup> Estimated frequency based on all clinical trial data.</p><p><sup>10</sup>Estimated frequency based on placebo-controlled clinical trials.</p><p>&nbsp;</p><p><em>c. Description of selected adverse reactions</em></p><p>Discontinuation of duloxetine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia or electric shock-like sensations, particularly in the head), sleep disturbances (including insomnia and intense dreams), fatigue, somnolence, agitation or anxiety, nausea and/or vomiting, tremor, headache, myalgia, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported reactions.</p><p>Generally, for SSRIs and SNRIs, these events are mild to moderate and self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when duloxetine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p>In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine-treated patients. HbA1c was stable in both duloxetine-treated and placebo-treated patients. In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine-treated group. There was also a small increase in fasting blood glucose and in total cholesterol in duloxetine-treated patients while those laboratory tests showed a slight decrease in the routine care group.</p><p>The heart rate-corrected QT interval in duloxetine-&shy;treated patients did not differ from that seen in placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients.</p><p><em>d. Paediatric population</em></p><p>A total of 509 paediatric patients aged 7 to 17 years with major depressive disorder and 241 paediatric patients aged 7 to 17 years with generalised anxiety disorder were treated with duloxetine in clinical trials. In general, the adverse reaction profile of duloxetine in children and adolescents was similar to that seen for adults.</p><p>A total of 467 paediatric patients initially randomized to duloxetine in clinical trials experienced a 0.1 kg mean decrease in weight at 10-weeks compared with a 0.9 kg mean increase in 353 placebo-treated patients. Subsequently, over the four- to six-month extension period, patients on average trended toward recovery to their expected baseline weight percentile based on population data from age- and gender-matched peers.</p><p>In studies of up to 9 months an overall mean decrease of 1% in height percentile (decrease of 2% in children (7-11 years) and increase of 0.3% in adolescents (12-17 years)) was observed in duloxetine-treated paediatric patients (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p>-National Pharmacovigilance center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340</p><p>o Reporting hotline: 19999&nbsp;</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 5400 mg were reported. Some fatalities have occurred, primarily with mixed overdoses, but also with duloxetine alone at a dose of approximately 1000 mg. Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.&nbsp;</p><p>No specific antidote is known for duloxetine but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. A free airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting absorption. Duloxetine has a large volume of distribution and forced diuresis, haemoperfusion, and exchange perfusion are unlikely to be beneficial.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antidepressants. ATC code: N06AX21.</p><p><em>Mechanism of action</em></p><p>Duloxetine is a combined serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors. Duloxetine&nbsp;dose-dependently increases extracellular levels of serotonin and noradrenaline in various brain areas of animals.</p><p><em>Pharmacodynamic effects</em></p><p>Duloxetine normalised pain thresholds in several preclinical models of neuropathic and inflammatory pain and attenuated pain behaviour in a model of persistent pain. The pain inhibitory action of duloxetine is believed to be a result of potentiation of descending inhibitory pain pathways within the central nervous system.</p><p><em>Clinical efficacy and safety</em></p><p><em>Major Depressive Disorder:</em> Cymbalta was studied in a clinical programme involving 3,158 patients (1,285 patient-years of exposure) meeting DSM-IV criteria for major depression. The efficacy of Cymbalta at the recommended dose of 60&nbsp;mg once a day was demonstrated in three out of three randomised, double-blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder. Overall, Cymbalta&rsquo;s efficacy has been demonstrated at daily doses between 60 and 120&nbsp;mg in a total of five out of seven randomised, double-blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder.</p><p>Cymbalta demonstrated statistical superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale (HAM-D) total score (including both the emotional and somatic symptoms of depression). Response and remission rates were also statistically significantly higher with Cymbalta compared with placebo. Only a small proportion of patients included in pivotal clinical trials had severe depression (baseline HAM-D&gt;25).</p><p>In a relapse prevention study, patients responding to 12-weeks of acute treatment with open-&shy;label Cymbalta 60&nbsp;mg once daily were randomised to either Cymbalta 60&nbsp;mg once daily or placebo for a further 6-months. Cymbalta 60&nbsp;mg once daily demonstrated a statistically significant superiority compared to placebo (p=0.004) on the primary outcome measure, the prevention of depressive relapse, as measured by time to relapse. The incidence of relapse during the 6-months double-blind follow-up period was 17% and 29% for duloxetine and placebo, respectively.</p><p>During 52 weeks of placebo-controlled double blind treatment, duloxetine-treated patients with recurrent MDD had a significantly longer symptom free period (p&lt;0.001) compared with patients randomised to placebo. All patients had previously responded to duloxetine during open-label duloxetine treatment (28 to 34 weeks) at a dose of 60 to 120 mg/day. During the 52-week placebo-controlled double blind treatment phase 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p&lt;0.001).</p><p>The effect of Cymbalta 60 mg once a day in elderly depressed patients (&sup3;65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17 score for duloxetine-treated patients compared to placebo. Tolerability of Cymbalta 60 mg once daily in elderly patients was comparable to that seen in the younger adults. However, data on elderly patients exposed to the maximum dose (120mg per day) are limited and thus, caution is recommended when treating this population.</p><p><em>Diabetic Peripheral Neuropathic Pain:</em> The efficacy of Cymbalta as a treatment for diabetic neuropathic pain was established in 2 randomised, 12-week, double-blind, placebo-controlled, fixed dose studies in adults (22 to 88 years) having diabetic neuropathic pain for at least 6 months. Patients meeting diagnostic criteria for major depressive disorder were excluded from these trials. The primary outcome measure was the weekly mean of 24-hour average pain, which was collected in a daily diary by patients on an 11-point Likert scale.</p><p>In both studies, Cymbalta 60&nbsp;mg once daily and 60&nbsp;mg twice daily significantly reduced pain compared with placebo. The effect in some patients was apparent in the first week of treatment. The difference in mean improvement between the two active treatment arms was not significant. At least 30% reported pain reduction was recorded in approximately 65% of duloxetine treated patients versus 40% for placebo. The corresponding figures for at least 50% pain reduction were 50% and 26% respectively. Clinical response rates (50% or greater improvement in pain) were analysed according to whether or not the patient experienced somnolence during treatment. For patients not experiencing somnolence, clinical response was observed in 47% of patients receiving duloxetine and 27% of patients on placebo. Clinical response rates in patients experiencing somnolence were 60% on duloxetine and 30% on placebo. Patients not demonstrating a pain reduction of 30% within 60 days of treatment were unlikely to reach this level during further treatment.</p><p>In an open label long-term uncontrolled study, the pain reduction in patients responding to 8-weeks of acute treatment of Cymbalta 60&nbsp;mg once daily was maintained for a further 6-months as measured by change on the Brief Pain Inventory (BPI) 24-hour average pain item.</p><p><em>Paediatric population</em></p><p>Duloxetine has not been studied in patients under the age of 7.</p><p>Two randomized, double-blind, parallel clinical trials were performed in 800 paediatric patients aged 7 to 17 years with major depressive disorder (see section 4.2). These two studies included a 10 week placebo and active (fluoxetine) controlled acute phase followed by six months period of active controlled extension treatment. Neither duloxetine (30-120 mg) nor the active control arm (fluoxetine</p><p>20-40 mg) statistically separated from placebo on change from baseline to endpoint in the Children&acute;s</p><p>Depression Rating Scale-Revised (CDRS-R) total score. Discontinuation due to adverse events was higher in patients taking duloxetine compared with those treated with fluoxetine, mostly due to nausea. During the 10-week acute treatment period, suicidal behaviours were reported (duloxetine 0/333 [0%], fluoxetine 2/225 [0.9%], placebo 1/220 [0.5%]). Over the entire 36-week course of the study, 6 out of 333 patients initially randomized to duloxetine and 3 out of 225 patients initially randomized to fluoxetine experienced suicidal behaviour (exposure adjusted incidence 0.039 events per patient year for duloxetine and 0.026 for fluoxetine). In addition, one patient who transitioned from placebo to duloxetine experienced a suicidal behaviour while taking duloxetine.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Cymbalta in all subsets of the paediatric population in the treatment of major depressive disorder, diabetic neuropathic pain and generalised anxiety disorder. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duloxetine is administered as a single enantiomer. Duloxetine is extensively metabolised by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6), followed by conjugation. The pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%), partly due to gender, age, smoking status and CYP2D6 metaboliser status.</p><p><em>Absorption:</em> Duloxetine is well absorbed after oral administration with a C<sub>max</sub> occurring 6 hours post dose. The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%). Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11 %). These changes do not have any clinical significance.</p><p><em>Distribution:</em> Duloxetine is approximately 96% bound to human plasma proteins. Duloxetine binds to both albumin and alpha-l acid glycoprotein. Protein binding is not affected by renal or hepatic impairment.</p><p><em>Biotransformation:</em> Duloxetine is extensively metabolised and the metabolites are excreted principally in urine. Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine. Based upon <em>in vitro </em>studies, the circulating metabolites of duloxetine are considered pharmacologically inactive. The pharmacokinetics of duloxetine in patients who are poor metabolisers with respect to CYP2D6 has not been specifically investigated. Limited data suggest that the plasma levels of duloxetine are higher in these patients.</p><p><em>Elimination:</em> The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours). After an intravenous dose the plasma clearance of duloxetine ranges from 22 l/hr to 46 l/hr (mean of 36 l/hr). After an oral dose the apparent plasma clearance of duloxetine ranges from 33 to 261 l/hr (mean 101 l/hr).</p><p><em>Special populations</em></p><p><em>Gender: </em>Pharmacokinetic differences have been identified between males and females (apparent plasma clearance is approximately 50% lower in females). Based upon the overlap in the range of clearance, gender-based pharmacokinetic differences do not justify the recommendation for using a lower dose for female patients.</p><p><em>Age: </em>Pharmacokinetic differences have been identified between younger and elderly females (&sup3;65 years) (AUC increases by about 25% and half-life is about 25% longer in the elderly), although the magnitude of these changes is not sufficient to justify adjustments to the dose. As a general recommendation, caution should be exercised when treating the elderly (see sections 4.2 and 4.4).</p><p><em>Renal impairment: </em>End stage renal disease (ESRD) patients receiving dialysis had 2-fold higher duloxetine C<sub>max</sub> and AUC values compared with healthy subjects. Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment.</p><p><em>Hepatic impairment: </em>Moderate liver disease (Child Pugh Class B) affected the pharmacokinetics of duloxetine. Compared with healthy subjects, the apparent plasma clearance of duloxetine was 79% lower, the apparent terminal half-life was 2.3 times longer, and the AUC was 3.7 times higher in patients with moderate liver disease. The pharmacokinetics of duloxetine and its metabolites have not been studied in patients with mild or severe hepatic insufficiency.</p><p><em>Breast-feeding mothers:</em> The disposition of duloxetine was studied in 6&nbsp;lactating women who were at least 12‑weeks postpartum. Duloxetine is detected in breast milk, and steady‑state concentrations in breast milk are about one‑fourth those in plasma. The amount of duloxetine in breast milk is approximately 7&nbsp;&micro;g/day while on 40&nbsp;mg&nbsp;twice daily dosing. Lactation did not influence duloxetine pharmacokinetics.</p><p><em>Paediatric population: </em>Pharmacokinetics of duloxetine in paediatric patients aged 7 to 17 years with major depressive disorder following oral administration of 20 to 120 mg once daily dosing regimen was characterized using population modelling analyses based on data from 3 studies. The model predicted duloxetine steady state plasma concentrations in paediatric patients were mostly within the concentration range observed in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Duloxetine was not genotoxic in a standard battery of tests and was not carcinogenic in rats.</p><p>Multinucleated cells were seen in the liver in the absence of other histopathological changes<strong> </strong>in the rat carcinogenicity study. The underlying mechanism and the clinical relevance are unknown.<strong><em> </em></strong>Female mice receiving duloxetine for 2 years had an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic microsomal enzyme induction. The relevance of this mouse data to humans is unknown. Female rats receiving duloxetine (45 mg/kg/day) before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (AUC). In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC). No malformations were observed in another study testing a higher dose of a different salt of duloxetine. In prenatal/postnatal toxicity studies in the rat, duloxetine induced adverse behavioural effects in the offspring at exposures below maximum clinical exposure (AUC).</p><p>Studies in juvenile rats reveal transient effects on neurobehaviour, as well as significantly decreased body weight and food consumption; hepatic enzyme induction; and hepatocellular vacuolation at 45 mg/kg/day. The general toxicity profile of duloxetine in juvenile rats was similar to that in adult rats. The no-adverse effect level was determined to be 20 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Hypromellose</p><p>Hypromellose acetate succinate</p><p>Sucrose</p><p>Sugar spheres</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Triethyl citrate</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>Gelatin</p><p>Sodium lauryl sulfate</p><p>Titanium dioxide (E171)</p><p>Indigo carmine (E132)</p><p>Yellow iron oxide (E172)</p><p>Edible white ink</p><p>&nbsp;</p><p>Edible white ink contains:</p><p>Titanium dioxide (E171)</p><p>Propylene glycol</p><p>Shellac</p><p>Povidone</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture. Store below 30&ordm; C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyvinylchloride (PVC), polyethylene (PE), and polychlorotrifluoroethylene (PCTFE) blister sealed with an aluminium foil.</p><p>Cymbalta 60&nbsp;mg is available in packs of 28, 56, 84 and 98 hard gastro-resistant capsules and in multipacks containing 100 (5 packs of 20) and 500 (25 packs of 20) hard gastro-resistant capsules.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 June 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>